Merck’s monoclonal antibody Enflonsia (clesrovimab) received FDA approval to prevent RSV lower respiratory tract disease in infants under 12 months, entering a competitive pediatric market alongside Sanofi's Beyfortus. This milestone comes as the CDC's Advisory Committee on Immunization Practices was fully disbanded by HHS Secretary Robert F. Kennedy Jr., introducing uncertainty to vaccination policies and potentially impacting rollout and recommendations for this critical therapy.